Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

ENBREL 1 ML — DIN 02242903

WATER : 1 ML ETANERCEPT : 25 MG · IMMUNEX CORPORATION · LIQUID ; POWDER FOR SOLUTION ; KIT · wholesale supply in Canada

Health Canada status: CANCELLED POST MARKET

What is ENBREL?

ENBREL 1 ML contains WATER : 1 ML ETANERCEPT : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02242903, held by IMMUNEX CORPORATION, supplied as LIQUID ; POWDER FOR SOLUTION ; KIT for SUBCUTANEOUS administration. Health Canada currently lists it as cancelled post market, status dated 31-Jan-2023. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.

What is ENBREL used for?

ENBREL is indicated for the treatment of moderately to severely active rheumatoid arthritis (RA) in adults, reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients aged 4 to 17 years, reducing signs and symptoms and inhibiting the progression of structural damage of active arthritis and improving physical function in adult patients with psoriatic arthritis (PsA), reducing signs and symptoms of active ankylosing spondylitis (AS), treatment of adult patients with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy, and treatment of pediatric patients ages 4 to 17 years with chronic severe PsO who are candidates for systemic therapy or phototherapy.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

How much does Etanercept cost around the world?

Etanercept is listed on 15 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.

What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Austria publishes a KVP (Kassenverkaufspreis); Bahrain publishes a retail (max). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.

MarketPrice basis published thereBrandsPacks listedRange
Australiaex-manufacturer4177AUD███.██
Norwaymax AUP (pharmacy retail)316NOK███.██
Luxembourgreimbursement1515EUR███.██
Czechiamax producer price (ex-factory)513CZK███.██
Greeceproducer price (ex-factory)1212EUR███.██
Italyex-factory (classe H)1212EUR███.██
Hungaryproducer price (ex-factory)1111HUF███.██
Icelandmax wholesale311ISK███.██
Slovakiacategorised final price1111EUR███.██
AustriaKVP (Kassenverkaufspreis)1010EUR███.██
Saudi Arabiapublic510SAR███.██
United Arab Emiratespublic49AED███.██
Bahrainretail (max)39BHD███.██
Romaniamax producer price58RON███.██
South Africasingle exit price57ZAR███.██

331 pack listings across 108 brand entries and 13 price bases, refreshed 08 Sep 2026. Ranges span every Etanercept pack in that market, so a high figure is usually a larger pack rather than the same product.

Figures are held for the Nexara team. Cross-market prices are published on incompatible bases and are not an offer, a landed cost, or a guide to what any buyer can obtain. Nexara publishes which markets list the product and on what basis; the numbers stay internal.

Team sign-in

This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.

Is there a generic Etanercept in Canada, and who makes it?

Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.

4 holders have a Canadian DIN containing Etanercept, across 10 DINs, of which 8 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.

Market authorization holderDINsMarketedBrand namesPosition
SANDOZ CANADA INCORPORATED33ERELZISourceable in Canada
LUPIN PHARMA CANADA LIMITED32RYMTISourceable in Canada
SAMSUNG BIOEPIS CO., LTD22BRENZYSSourceable in Canada
IMMUNEX CORPORATION21ENBRELSourceable in Canada

Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.

How is it supplied and stored?

Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.

Strength on the label1 ML
Dosage formLIQUID ; POWDER FOR SOLUTION ; KIT
RouteSUBCUTANEOUS
Pack configuration (monograph)ENBREL single-use prefilled syringes are available in 25 mg* (0.51 mL of a 50 mg/mL solution of etanercept, minimum deliverable volume of 0.47 mL) and 50 mg (0.98 mL of a 50 mg/mL solution of etanercept, minimum deliverable volume of 0.94 mL) dosage strength. ENBREL SureClick® autoinjectors are available in 50 mg (0.98 mL of a 50 mg/mL solution of etanercept, minimum deliverable volume of 0.94 mL) dosage strength. ENBREL 25 mg* and 50 mg single-use prefilled syringes and ENBREL 50 mg single-use prefilled SureClick® autoinjectors are supplied in cartons containing four syringes or autoinjectors with 27-gauge, ½ inch needles. A single syringe or autoinjector replacement carton is available if needed. ENBREL multiple-use vial is supplied in a carton containing four dose trays. Each dose tray contains one 25 mg vial of etanercept, one diluent syringe (1 mL Sterile Bacteriostatic Water for Injection, USP, containing 0.9% benzyl alcohol), one 27-gauge ½ inch needle, one vial adapter, and one plunger. Each carton contains four “Mixing Date:” stickers. A single dose replacement tray is available, if needed.
Storagenull

Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.

Substance and classification

Active substanceEtanercept
ATC codeL04AB01
AHFS class90:24.16.92
Biosimilar biologicNo

Health Canada record and identifiers

The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.

DIN (8-digit, as used in ordering)02242903
DIN (unpadded, as printed on some documents)2242903
Brand nameENBREL
Generic / active ingredientWATER : 1 ML ETANERCEPT : 25 MG
Market authorization holderIMMUNEX CORPORATION
Health Canada schedulePrescription
ATC codeL04AB01
ATC anatomical main groupL — Antineoplastic and immunomodulating agents
ATC therapeutic subgroupL04AB
Current statusCANCELLED POST MARKET
Status date31-Jan-2023
Original market date2001-03-14 00:00:00
Status sourceLive Health Canada DPD sync

Verify on the primary sources

Health Canada DPD record Approved product monograph (PDF)

What can be used instead?

Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.

1 · Same molecule, other Canadian presentations

8 of 10 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.

ProductStrengthFormHolderHealth Canada statusDIN
BRENZYS50 MGSOLUTIONSAMSUNG BIOEPIS CO., LTDMARKETED02455323
BRENZYS50 MGSOLUTIONSAMSUNG BIOEPIS CO., LTDMARKETED02455331
ENBREL50 MGSOLUTIONIMMUNEX CORPORATIONMARKETED02274728
ERELZI50 MGSOLUTIONSANDOZ CANADA INCORPORATEDMARKETED02462869
ERELZI50 MGSOLUTIONSANDOZ CANADA INCORPORATEDMARKETED02462850
ERELZI25 MG / 0.5 MLSOLUTIONSANDOZ CANADA INCORPORATEDMARKETED02462877
RYMTI50 MG / 1 MLSOLUTIONLUPIN PHARMA CANADA LIMITEDMARKETED02530295
RYMTI50 MG / 1 MLSOLUTIONLUPIN PHARMA CANADA LIMITEDMARKETED02530309
RYMTI25 MG / 0.5 MLSOLUTIONLUPIN PHARMA CANADA LIMITEDAPPROVED02530287

2 · Same class — other molecules in ATC L04AB

MoleculeCanadian brandsDINsMarketedSourceable
AdalimumabABRILADA · AMGEVITA · HADLIMA · HADLIMA PUSHTOUCH · +6 more4134Yes
EtanerceptBRENZYS · ENBREL · ERELZI · RYMTI108Yes
InfliximabAVSOLA · IXIFI · OMVYENCE · REMDANTRY · +4 more96Yes
GolimumabLIVMOTY · SIMPONI · SIMPONI I.V.95Yes
Certolizumab PegolCIMZIA22Yes

A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.

3 · Adjacent classes in ATC L04A

ATC subgroupMoleculesDINsMarketed
L04AXAzathioprine · Dimethyl Fumarate · Lenalidomide · Methotrexate · Other Immunosuppressants · +3 more191124
L04ACAnakinra · Basiliximab · Bimekizumab · Brodalumab · Canakinumab · +13 more8575
L04AAAbatacept · Alefacept · Antilymphocyte Immunoglobulin (Horse) · Antithymocyte Immunoglobulin (Rabbit) · Apremilast · +4 more7342
L04ADCiclosporin · Tacrolimus4930
L04AKLeflunomide · Teriflunomide4425
L04AHEverolimus · Sirolimus3623
L04AFBaricitinib · Deucravacitinib · Ritlecitinib · Tofacitinib · Upadacitinib2319
L04AGAlemtuzumab · Anifrolumab · Belimumab · Efalizumab · Inebilizumab · +7 more2015

Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.

What else is ENBREL called?

The same molecule, Etanercept, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:

NameScriptRegistered in
ErelziLatinAustralia, Bahrain, Czechia, Iceland, Norway, Saudi Arabia
NepextoLatinAustralia, Bahrain, Czechia, Saudi Arabia
BrenzysLatinAustralia, Saudi Arabia
BenepaliLatinCzechia, Iceland, Norway
ENBREL PRO PEDIATRICK� POU�IT�LatinCzechia

Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.

Can this still be bought in Canada?

No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.

If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Why is there no price on this page?

Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Sources and disclaimer

Product data sourced from the Health Canada Drug Product Database and the approved product monograph (PDF). Health Canada status reconciled against the live DPD sync. Last reviewed 10 Sep 2026.

Nothing on this page is medical advice. Nexara Health is a licensed wholesale distributor and supplies licensed entities only; consumer orders are routed to a partner pharmacy. Alternatives tables describe supply, not clinical equivalence.

Health Canada Drug Product Database (DPD), DIN 02242903. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.